ReviewFrontiers in oncology2020
EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Burden of Epstein-Barr virus in gastric cancer, nasopharyngeal carcinoma, and Burkitt lymphoma in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Pooled it
- Review
- Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases.Annals of surgical oncology · 2026Review
- Article
- EBV Genome Variations and Association With Diseases.Journal of medical virology · 2026Review
- Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Beyond <italic>Helicobacter pylori</italic>: Current Insights into <italic>H. pylori</italic>-Naive Gastric Cancer.Digestion · 2026Review
- First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients.Cancer biology & medicine · 2026Review
- Development of a clinical scoring tool using machine-learning prediction of monospot positivity in suspected infectious mononucleosis.FEMS microbes · 2026Article
- Epstein-Barr virus-associated tumors: commonalities in pathogenesis and the tumor immune microenvironment.Frontiers in immunology · 2026Review
- Gastric cancer in China: Epidemiology, risk factors, and screening.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- An overview of hepatitis B virus in gastric carcinogenesis: from clinical association to molecular mechanisms.Infectious agents and cancer · 2025Review
- MUC1-C auto-regulatory complex with EBNA1 is responsible for latent Epstein-Barr virus-associated gastric cancer progression.Oncogene · 2025Article
- FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity.The Journal of molecular diagnostics : JMD · 2025Article
- Identification of Epstein-Barr virus BORF2 sequences required for APOBEC3B relocalization.Journal of virology · 2025Article
- Missing link: Viral RNA signatures in circulating exosomes as early diagnostic biomarkers for gastrointestinal cancers.World journal of gastrointestinal oncology · 2025Article
- Genome integration of human DNA oncoviruses.Journal of virology · 2025Review
- Herpesvirus-associated diseases: biomarkers and advancements in clinical research.Virology journal · 2025Review
- Gastric carcinoma harbouring loss‑of‑function mutations in theOncology letters · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is the fifth most common malignant tumor and second leading cause of cancer-related deaths worldwide. With the improved understanding of gastric cancer, a subset of gastric cancer patients infected with Epstein-Barr virus (EBV) has been identified. EBV-positive gastric cancer is a type of tumor with unique genomic aberrations, significant clinicopathological features, and a good prognosis. After EBV infects the human body, it first enters an incubation period in which the virus integrates its DNA into the host and expresses the latent protein and then affects DNA methylation through miRNA under the action of the latent protein, which leads to the occurrence of EBV-positive gastric cancer. With recent developments in immunotherapy, better treatment of EBV-positive gastric cancer patients appears achievable. Moreover, studies show that treatment with immunotherapy has a high effective rate in patients with EBV-positive gastric cancer. This review summarizes the research status of EBV-positive gastric cancer in recent years and indicates areas for improvement of clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.